Shinyu Izumi

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Inhaled GM-CSF for Pulmonary Alveolar Proteinosis

Ryushi Tazawa, Takahiro Ueda, Mitsuhiro Abe et al. · New England Journal of Medicine · 2019 · 155 citations · Full text

Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19

Masaya Sugiyama, Noriko Kinoshita, Satoshi Ide et al. · Gene · 2020 · 104 citations · Full text

Disease Progression, Severe/critical Disease, Medicine +11

The Importance of Bacterial and Viral Infections Associated with Adult Asthma Exacerbations in Clinical Practice

Motoyasu Iikura, Masayuki Hojo, Rikiya Koketsu et al. · PLoS ONE · 2015 · 103 citations · Full text

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 96 citations · Full text

Fibrosis, Extracellular Matrix Turnover, Inflammatory Lung Disease +7